Price$11.18+0.66 (+6.27%)
01:30 PM07:45 PM
News · 26 weeks62-72%
2025-11-022026-04-26
Mix3690d
- Insider23(64%)
- SEC Filings7(19%)
- Market5(14%)
- Other1(3%)
Latest news
25 items- NEWSClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026SOLANA BEACH, CA / ACCESS Newswire / April 29, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 first quarter on Wednesday, May 13th, after the market close.Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 first quarter results on Wednesday, May 13th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (
- SECSEC Form DEFA14A filed by ClearPoint Neuro Inc.DEFA14A - ClearPoint Neuro, Inc. (0001285550) (Filer)
- NEWSClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global FootprintSOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced the successful completion of the first clinical procedure utilizing the 510(k)-cleared Velocity Alpha MR High Speed Surgical Drill System. Utilized in a four-trajectory clinical trial procedure, the system highlights its scalability and potential to support a broader range of programs within the Company's partnered biologics portfolio.The Velocity Alpha MR High Speed Surgical Drill is manufactured by a German-based surgical equipment leader, adeor medical AG, and it
- NEWSClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global FootprintCombined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's overall global infrastructure in support of its strategy to enable 20,000 cell and gene therapy procedures annually. SOLANA BEACH, CA / ACCESS Newswire / April 20, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of a Medical Device License (MDL) from Health Canada for its Neuro Navigation System, further expanding our Drug Delivery ecosystem and global footpr
- SECSEC Form DEF 14A filed by ClearPoint Neuro Inc.DEF 14A - ClearPoint Neuro, Inc. (0001285550) (Filer)
- INSIDERSEC Form 4 filed by Fletcher R John4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by Girin Pascal E R4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by Richards Timothy T.4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ClearPoint Neuro Inc.SCHEDULE 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)
- INSIDERSEC Form 4 filed by Burnett Joseph4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- SECSEC Form 10-K filed by ClearPoint Neuro Inc.10-K - ClearPoint Neuro, Inc. (0001285550) (Filer)
- SECClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)
- NEWSClearPoint Neuro Reports Fourth Quarter and Full Year 2025 ResultsRecord Revenue and IRRAS Holdings Acquisition Highlight the Company's 'Fast. Forward.' StrategySOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full year ended December 31, 2025.2025 Full Year and Fourth Quarter HighlightsReported fourth quarter revenue of $10.4 million, including $1.2 million of IRRAflow revenue, representing 34% overall growth and 19% year-over-year organic growth compared with the fourth quarter of 2024;Reported revenue of $37.0 million for the fu
- INSIDERChief Financial Officer D'Alessandro Danilo covered exercise/tax liability with 16,601 shares and converted options into 32,627 shares, increasing direct ownership by 18% to 102,684 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERCEO and President Burnett Joseph converted options into 84,829 shares and covered exercise/tax liability with 43,161 shares, increasing direct ownership by 77% to 95,900 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERChief Business Officer Stigall L. Jeremy converted options into 30,995 shares and covered exercise/tax liability with 15,151 shares, increasing direct ownership by 17% to 108,482 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERChief Operating Officer Sabra Mazin converted options into 26,101 shares and covered exercise/tax liability with 13,281 shares, increasing direct ownership by 24% to 67,343 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERChief Financial Officer D'Alessandro Danilo converted options into 4,145 shares and covered exercise/tax liability with 2,109 shares, increasing direct ownership by 2% to 86,658 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERChief Business Officer Stigall L. Jeremy converted options into 8,291 shares and covered exercise/tax liability with 3,224 shares, increasing direct ownership by 6% to 92,638 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by ClearPoint Neuro Inc.4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by ClearPoint Neuro Inc.4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by ClearPoint Neuro Inc.4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERChief Financial Officer D'Alessandro Danilo converted options into 18,765 shares and covered exercise/tax liability with 9,548 shares, increasing direct ownership by 12% to 84,622 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- NEWSClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026SOLANA BEACH, CA / ACCESS Newswire / March 6, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2025 fourth quarter and full year on Tuesday, March 17th, after the market close.Investors and analysts are invited to listen to the live broadcast review of the Company's 2025 fourth quarter and full year results on Tuesday, March 17th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do
- INSIDERCEO and President Burnett Joseph converted options into 26,568 shares and covered exercise/tax liability with 9,533 shares, increasing direct ownership by 136% to 29,534 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
CLPT FAQ
6 questionsWhat does ClearPoint Neuro Inc. do?
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally...Where does CLPT stock trade?
ClearPoint Neuro Inc. (CLPT) is listed on NASDAQ.What sector and industry is CLPT in?
ClearPoint Neuro Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about CLPT?
ClearPoint Neuro Inc. has had 4 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $1000.00 price target on 2024-07-25. Recent price targets range from $800.00 to $1500.00.What companies are similar to CLPT?
Notable peers in the same industry include SYK (Stryker Corporation), BSX (Boston Scientific Corporation), MMM (3M Company), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare CLPT side-by-side with any of them on Quantisnow.How can I track CLPT on Quantisnow?
Quantisnow aggregates ClearPoint Neuro Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLPT to receive live email and push alerts on every new disclosure.